Vectorite Biomedical Inc. (TPEX:4170)
Taiwan
· Delayed Price · Currency is TWD 13.45
-0.65 (-4.61%)
At close: Mar 9, 2026
Vectorite Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 67.9 | 57.77 | 55.85 | 42.91 | 28.77 | 24.54 | Upgrade
|
| Revenue Growth (YoY) | 26.97% | 3.43% | 30.15% | 49.16% | 17.22% | -7.52% | Upgrade
|
| Cost of Revenue | 40.89 | 40.8 | 39.43 | 42.21 | 31.24 | 22.63 | Upgrade
|
| Gross Profit | 27 | 16.97 | 16.42 | 0.71 | -2.47 | 1.92 | Upgrade
|
| Selling, General & Admin | 27.13 | 25.98 | 25.96 | 25.82 | 26.69 | 37.22 | Upgrade
|
| Research & Development | 17.99 | 16.96 | 6.59 | 5.43 | 13.25 | 25.63 | Upgrade
|
| Operating Expenses | 45.12 | 42.94 | 32.56 | 31.24 | 39.95 | 62.84 | Upgrade
|
| Operating Income | -18.12 | -25.97 | -16.13 | -30.54 | -42.43 | -60.93 | Upgrade
|
| Interest Expense | -0.01 | - | - | - | - | -0.54 | Upgrade
|
| Interest & Investment Income | 3.04 | 3.19 | 3.55 | 1.97 | 0.87 | 0.14 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -5.84 | -14.96 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.81 | 0.5 | 0.1 | -0.1 | 0.05 | 0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.23 | 4.38 | 2.7 | 3.2 | 4.63 | 3.27 | Upgrade
|
| EBT Excluding Unusual Items | -12.67 | -17.91 | -9.78 | -25.48 | -42.72 | -72.86 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.43 | -6.4 | 3.88 | -0.98 | 51.05 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | - | - | - | - | 1 | Upgrade
|
| Asset Writedown | -16.02 | -15.77 | -0.73 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.16 | Upgrade
|
| Pretax Income | -23.22 | -40.07 | -6.63 | -26.45 | 8.33 | -71.69 | Upgrade
|
| Earnings From Continuing Operations | -23.22 | -40.07 | -6.63 | -26.45 | 8.33 | -71.69 | Upgrade
|
| Minority Interest in Earnings | 0.03 | 0.02 | 0.03 | 0.04 | 0.03 | 3.52 | Upgrade
|
| Net Income | -23.19 | -40.05 | -6.6 | -26.41 | 8.36 | -68.17 | Upgrade
|
| Net Income to Common | -23.19 | -40.05 | -6.6 | -26.41 | 8.36 | -68.17 | Upgrade
|
| Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 43 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 43 | 29 | Upgrade
|
| Shares Change (YoY) | -0.14% | -0.14% | - | 1.84% | 47.01% | 14.34% | Upgrade
|
| EPS (Basic) | -0.53 | -0.92 | -0.15 | -0.60 | 0.19 | -2.33 | Upgrade
|
| EPS (Diluted) | -0.53 | -0.92 | -0.15 | -0.60 | 0.19 | -2.34 | Upgrade
|
| Free Cash Flow | -10.15 | -14.35 | -3.46 | 13.81 | -67.59 | -37.67 | Upgrade
|
| Free Cash Flow Per Share | -0.23 | -0.33 | -0.08 | 0.32 | -1.57 | -1.29 | Upgrade
|
| Gross Margin | 39.77% | 29.37% | 29.40% | 1.65% | -8.60% | 7.81% | Upgrade
|
| Operating Margin | -26.69% | -44.96% | -28.88% | -71.16% | -147.47% | -248.24% | Upgrade
|
| Profit Margin | -34.16% | -69.33% | -11.82% | -61.55% | 29.05% | -277.75% | Upgrade
|
| Free Cash Flow Margin | -14.95% | -24.84% | -6.19% | 32.19% | -234.93% | -153.49% | Upgrade
|
| EBITDA | -9.61 | -17.21 | -6.97 | -21.68 | -25.94 | -42.72 | Upgrade
|
| EBITDA Margin | -14.16% | -29.79% | -12.48% | -50.51% | -90.15% | -174.06% | Upgrade
|
| D&A For EBITDA | 8.51 | 8.76 | 9.16 | 8.86 | 16.49 | 18.21 | Upgrade
|
| EBIT | -18.12 | -25.97 | -16.13 | -30.54 | -42.43 | -60.93 | Upgrade
|
| EBIT Margin | -26.69% | -44.96% | -28.88% | -71.16% | -147.47% | -248.24% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.